FeNO-guided treatment with inhaled corticosteroids/long-acting β2-agonists significantly reduced eosinophilic airway inflammation compared to treatment with long-acting muscarinic antagonists in COPD。
When clinically treating COPD, FeNO can be used to aid drug selection. More precise treatment for COPD patients.